Anhye Kim

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 20

Top Topics

Idiopathic Pulmonary Fibrosis

Top Venues

Expert opinion on biological therapy

Clinical and translational science

Translational and clinical pharmacology

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Wonsuk Shin, Min Young Park, Jongwoo Kim, Jihyeon Kim, Jun Hee Nam, Jongwon Choi, A-Young Yang, Hyounggyoon Yoo, Yil-Seob Lee, Anhye Kim
No drug-drug interactions between selective prolyl-tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants. Clinical and translational science 17 (1) (2024)
Anhye Kim, Jang Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin Gyu Jung, Jean-Yves Reginster, SungHyun Kim, YunJu Bae, JeeHye Suh, Sera Kim, EunKyung Lee, Stuart L Silverman
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert opinion on biological therapy (2024)
Wonsuk Shin, Min Young Park, Jongwoo Kim, Jihyeon Kim, Jun Hee Nam, Jongwon Choi, A-Young Yang, Hyounggyoon Yoo, Yil-Seob Lee, Anhye Kim
No drug-drug interactions between selective prolyl-tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants. Clinical and translational science 17 (1) (2024)
Anhye Kim, Jang-Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin Gyu Jung, Jean-Yves Reginster, SungHyun Kim, YunJu Bae, JeeHye Suh, Sera Kim, EunKyung Lee, Stuart L Silverman
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert opinion on biological therapy 24 (7) (2024)
Anhye Kim, Jang-Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin Gyu Jung, Jean-Yves Reginster, SungHyun Kim, YunJu Bae, JeeHye Suh, Sera Kim, EunKyung Lee, Stuart L Silverman
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert opinion on biological therapy (2024)
Anhye Kim, Jang-Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin Gyu Jung, Jean-Yves Reginster, SungHyun Kim, YunJu Bae, JeeHye Suh, Sera Kim, EunKyung Lee, Stuart L Silverman
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert opinion on biological therapy 24 (7) (2024)
Anhye Kim, Jang-Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin Gyu Jung, Jean-Yves Reginster, SungHyun Kim, YunJu Bae, JeeHye Suh, Sera Kim, EunKyung Lee, Stuart L Silverman
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert opinion on biological therapy (2024)
Anhye Kim, Jang-Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin Gyu Jung, Jean-Yves Reginster, SungHyun Kim, YunJu Bae, JeeHye Suh, Sera Kim, EunKyung Lee, Stuart L Silverman
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert opinion on biological therapy 24 (7) (2024)
Maria Park, Suein Choi, Sungpil Han, Wonsuk Shin, Anhye Kim, Seunghoon Han, Bomin Kim, Yeji Lim, Hyounggyoon Yoo
Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function. Translational and clinical pharmacology 31 (4) (2023)
A-Young Yang, Hyounggyoon Yoo, Wonsuk Shin, Yil-Seob Lee, Hyejung Lee, Sung-Eun Kim, Anhye Kim
Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation. Translational and clinical pharmacology 31 (1) (2023)
Wonsuk Shin, Min Young Park, Jongwoo Kim, Jihyeon Kim, Jun Hee Nam, Jongwon Choi, A-Young Yang, Hyounggyoon Yoo, Yil-Seob Lee, Anhye Kim
No drug-drug interactions between selective prolyl-trna synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants. Clinical and translational science (2023)
Maria Park, Suein Choi, Sungpil Han, Wonsuk Shin, Anhye Kim, Seunghoon Han, Bomin Kim, Yeji Lim, Hyounggyoon Yoo
Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function. Translational and clinical pharmacology 31 (4) (2023)
Wonsuk Shin, Min Young Park, Jongwoo Kim, Jihyeon Kim, Jun Hee Nam, Jongwon Choi, A-Young Yang, Hyounggyoon Yoo, Yil-Seob Lee, Anhye Kim
No drug-drug interactions between selective prolyl-trna synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants. Clinical and translational science (2023)
Sungyeun Bae, Ki Young Huh, Jaeseong Oh, Kyung-Sang Yu, Anhye Kim
Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Sungyeun Bae, Ki Young Huh, Jaeseong Oh, Kyung-Sang Yu, Anhye Kim
Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Wonsuk Shin, A-Young Yang, Hyung Park, Hyejung Lee, Hyounggyoon Yoo, Anhye Kim
A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State. Pharmaceuticals (Basel, Switzerland) 16 (8) (2023)
Wonsuk Shin, Min Young Park, Jongwoo Kim, Jihyeon Kim, Jun Hee Nam, Jongwon Choi, A-Young Yang, Hyounggyoon Yoo, Yil-Seob Lee, Anhye Kim
No drug-drug interactions between selective prolyl-trna synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants. Clinical and translational science (2023)
Wonsuk Shin, Min Gul Kim, Anhye Kim
Comparison of international guidelines for early-phase clinical trials of cellular and gene therapy products. Translational and clinical pharmacology 30 (1) (2022)
Anhye Kim, Stephen R Dueker, Feng Dong, Ad F Roffel, Sang-Won Lee, Howard Lee
Human ADME for YH12852 using wavelength scanning cavity ring-down spectroscopy (WS-CRDS) after a low radioactivity dose. Bioanalysis 12 (2) (2020)
Wonsuk Shin, A-Young Yang, Hyeonji Yun, Doo-Yeoun Cho, Kyung Hee Park, Hyunju Shin, Anhye Kim
Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects. Translational and clinical pharmacology 28 (3) (2020)